Etodolac has not been completely discontinued, but the branded version (Lodine) is no longer sold, and the drug has become significantly harder to find. Several generic manufacturers still produce etodolac tablets and capsules, but fewer pharmacies stock it, fewer doctors prescribe it, and its market presence has been shrinking steadily since 2018. The reasons come down to a combination of patent expiration, generic price collapse, safety concerns shared by all NSAIDs, and competition from alternatives that edged it out clinically.
The Branded Version Is Gone
Lodine, the original brand name for etodolac, was pulled from the market after its patent protection expired. Once the patent expired in the United States in 2018, generic manufacturers flooded the market, and the branded product could no longer compete on price. This is a common pattern: when a drug loses patent exclusivity and doesn’t have a unique enough clinical profile to justify brand-name pricing, the manufacturer stops producing the branded version entirely.
Generic etodolac still exists. Companies including Taro Pharmaceuticals, Zydus Lifesciences, ANI Pharmaceuticals, and others currently hold active labels for etodolac tablets, capsules, and extended-release formulations. So if your doctor prescribes it, a pharmacy can still order it. But no new formulations or indications have been approved since 2018, meaning there’s been no investment in keeping etodolac competitive in the market. Projected sales have been declining year over year, dropping from roughly $150 million in 2023 toward an expected $115 million by 2028.
Safety Warnings Hurt Its Reputation
Etodolac carries the same black box warnings that apply to all NSAIDs, but these warnings have played a role in its declining popularity. The FDA requires a prominent cardiovascular warning stating that NSAIDs may increase the risk of serious blood clots, heart attacks, and strokes, and that this risk grows with longer use. People with existing heart disease or risk factors face even greater danger. Etodolac is also specifically contraindicated for pain management around coronary artery bypass graft surgery.
The gastrointestinal warning is equally serious. NSAIDs raise the risk of stomach and intestinal bleeding, ulcers, and perforation, all of which can be fatal. These events can happen at any point during treatment and without any warning symptoms. Older adults face the highest risk. While these warnings apply broadly to NSAIDs as a class, they made it harder for etodolac to maintain market share when alternatives with better-studied safety profiles were available.
Better Alternatives Took Over
Etodolac occupies an unusual middle ground in pain management. It’s a COX-2 selective inhibitor, meaning it preferentially blocks the enzyme responsible for inflammation while being somewhat gentler on the stomach lining than fully nonselective NSAIDs like naproxen. Studies confirmed that etodolac caused fewer serious upper gastrointestinal events compared to naproxen. Its selectivity falls somewhere between older NSAIDs and dedicated COX-2 inhibitors like celecoxib (Celebrex).
That in-between status became a problem. Celecoxib, the most widely prescribed COX-2 selective NSAID, proved superior to etodolac for controlling acute postoperative pain in head-to-head trials. In one multicenter, double-blind study, celecoxib achieved a 76.2% efficacy rate compared to etodolac’s 68.0%, a statistically significant difference. Celecoxib also showed a safety profile similar to placebo in that trial, with no adverse events unique to the drug. For doctors choosing between two COX-2 selective options, celecoxib offered a clear edge in both effectiveness and supporting evidence.
Meanwhile, for patients who didn’t need COX-2 selectivity, cheap and widely available options like ibuprofen and naproxen remained the default first-line choices. Etodolac ended up squeezed from both directions: not selective enough to compete with celecoxib, not cheap or familiar enough to compete with over-the-counter NSAIDs.
Why Your Pharmacy May Not Carry It
Even though generic etodolac is still technically manufactured, you may have trouble filling a prescription. Pharmacies stock medications based on demand, and as prescribing rates drop, fewer locations keep etodolac on their shelves. A pharmacy can usually special-order it, but this adds delays. Some insurance formularies have also moved etodolac to less favorable tiers or dropped it entirely, steering patients and prescribers toward preferred alternatives.
If you were previously taking etodolac and can no longer find it, your doctor will likely switch you to another NSAID. Celecoxib is the closest match in terms of COX-2 selectivity and stomach-friendliness. For general pain and inflammation, ibuprofen, naproxen, or meloxicam are common substitutes, though each has its own risk profile worth discussing with your prescriber.
Is Etodolac Coming Back?
There’s no indication that etodolac will regain significant market presence. No pharmaceutical company has filed for new formulations, new indications, or updated patents. The drug isn’t unsafe enough to be pulled from the market by regulators, but it’s also not clinically distinct enough to attract renewed investment. It will likely continue its slow fade as existing generic manufacturers weigh whether production remains profitable at ever-lower price points.